Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bisphosphocin Nu-3 for Infected Diabetic Ulcers
NCT02737722Phase 2Completed
- Sponsor
- Lakewood-Amedex Biotherapeutics
- Start
- Apr 2016
- Primary completion
- Aug 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic foot ulcer (DFU) comparing Bisphosphocin Nu-3 with Placebo (2 arms). Primary endpoints: Treatment-related Treatment-emergent Adverse Events at Day 15 and Number of Participants With Normal and Abnormal Cultures at Day 15. Started Apr 2016; status: completed.
02
Drugs
bisphosphocin nu-3
03
Conditions
diabetic foot ulcer (DFU)
Beyond the preview
Go deeper on NCT02737722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737722.